If approved, Veradermics' VDPHL01 could become the first hair loss drug to secure the regulatory go-ahead in nearly three decades.

Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) combination therapy met one key secondary endpoint but miss ...

Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

Cellenkos has received FDA clearance to begin its Phase II clinical trial of CK0801 for the treatment of aplastic anaemia.

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.

Kyowa Kirin and Kura Oncology have begun a Japanese Phase II registrational study of ziftomenib in adult patients with r/r NPM1-mutated AML.

Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30 as a treatment for type 2 diabetes mellitus (T2DM).

Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.

Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV infections.

CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

Roche will be launching the Phase III trial to gain approval of Elevidys in Europe and other countries globally.